A2M – UBS rates the stock as Buy

UBS pins its Buy rating on a meaningful recovery in indirect infant formula sales over the next two years, plus substantial gains in market share in China through the off-line roll-out and free trade zone expansion.

The broker acknowledges short-term earnings risks amid reduced visibility on daigou sales and the conflicting messages from peers in the March quarter. Target is steady at NZ$16.00.

Sector: Food, Beverage & Tobacco.

 

Current Price is $7.71. Target price not assessed.

 

 

About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →